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1.ABSTRACT 
 
The objective of the present study was to develop Gliclazide microspheres in 
order to achieve an extended retention in the upper GIT. Which may result in enhance 
the absorption and improve the bioavailability. The microspheres were prepared by 
emulsion solvent diffusion-evaporation method using different ratios of rate controlling 
polymer poloxamer 407, Gliclazide is used in each formulation at constant ratio. The 
mixture of dichloromethane and ethanol at ratio of (1:1), with tween 80 as the 
surfactant. The prepared microspheres were evaluated for percentage yield, particle 
size, entrapment efficiency, shape and surface characterization, in vitro dissolution 
studies and drug release mechanism was interpretated by kinetic model. The effect of 
polymer concentration on these parameters was investigated. The studies revealed that 
increase in concentration of hydrophilic non-ionic polymer (Poloxamer 407) increased 
the drug release from the microspheres. The formulation F6 (Gliclazide:poloxamer 407 
is 1:6) was selected as best formulation, and it follows zero order drug release with 
89.36% entrapment efficiency, 98.16% drug content, 93.85% In-vitro drug release at 
12thhour.
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2. INTRODUCTION 
Oral drug delivery is the most widely used route of administration among all 
the routes that have been explored for systemic delivery of drugs via pharmaceutical 
products of different dosage form. Oral route is considered most popular, convenient 
and safe due to ease of administration, patient acceptance, and cost-effective 
manufacturing process. (1) 
 Most of the pharmaceutical products designed for oral delivery are 
conventional drug delivery systems. Problem encountered with conventional dosage 
forms are: drugs with short half life require frequent administration, which may 
increase chance of missing dose of drug leading to poor patient compliance. 
Fluctuations in drug plasma concentration this may accumulate side effects. (2, 3) 
 In order to overcome the drawbacks of conventional drug delivery system, 
several technical advancements have led to development of controlled drug delivery 
system that could revolutionize method of medication and provide a number of 
therapeutic benefits.(4) 
CONTROLLED DRUG DELIVERY SYSTEM (5) 
  Controlled release systems include any drug delivery systems that achieve 
slow release of drug over an extended period of time. 
 Drugs that are easily absorbed from the gastrointestinal tract (GIT) and have a 
short half-life are eliminated quickly from the blood circulation, so they require 
frequent dosing. To avoid this drawback, the oral controlled release formulations have 
been developed in an attempt to release the drug slowly into the GIT and maintain an 
effective drug concentration in the serum for longer period of time. 
  However, such oral drug delivery devices have a physiological limitation of 
gastric retention time (GRT). Variable and short gastric emptying time can result in 
incomplete drug release from the drug delivery system (DDS) in the absorption zone 
i.e. stomach or upper part of small intestine, this leads to diminished efficacy of the 
administered dose.  
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 To overcome these limitations, several approaches being proposed to prolong 
the GRT include microspheres; mucoadhesive systems; high-density systems; 
modified-shape systems and other delayed gastric emptying devices.  
 Microspheres are among the several approaches that have been developed to 
increase the GRT of dosage forms. This Gastro retentive microspheres drug delivery 
system  have a bulk density lower than that of gastric fluids and thus remains buoyant 
in the stomach without affecting gastric emptying rate for a prolonged period of time 
.While the system is releasing on gastric contents, the drug is released slowly at a 
desired rate from the system. 
  Both single and multiple unit systems have been developed. Single-unit 
systems are unreliable in prolonging the GRT owing to their ‘all-or-nothing’ 
emptying process and, thus, may result in high variability in bioavailability and local 
irritation due to a large amount of drug delivered at a particular site of GIT. In 
contrast, multiple-unit particulate dosage forms (e.g. microspheres) have the 
advantages that they pass uniformly through the GIT to avoid the vagaries of gastric 
emptying and provide an adjustable release, thereby reducing the inter subject 
variability in absorption and risk of local irritation. 
Various multiple-unit microspheres systems have been developed in different 
forms and are based on various principles, such as air compartment multiple-unit 
system; micro particles based on porous carriers; hollow microspheres ; oil-entrapped 
gel beads. 
 Various natural, semi synthetic and synthetic polymers have been used in the 
development of  microspheres to entrap the drug. As a microsphere polymer 
poloxamer has been investigated extensively because it forms gelataneous mass and 
increase on the gastric contents. And it is non toxic and eliminated easily from the 
body. Ethyl cellulose (EC) is used as co-polymer which increases the stability of 
polymer poloxamer, and provides good drug release barrier, it also aids to improve 
buoyancy. (6) 
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Diabetes 
 It is a complex metabolic disorder resulting in hyperglycaemia. 
Hyperglycaemia may be attributed to defects in pancreatic β- cells, insulin secretion, 
hepatic glucose output, glucose uptake of peripheral tissues and immune function. 
Polyurea (frequent urination) and polyphagia (increased hunger) are the symptoms of 
diabetes. (7) 
Diabetes mellitus is classified into two types, insulin dependent diabetes 
mellitus (type-I) and non insulin dependent diabetes mellitus (type-II). Type-I 
diabetes occurs due to the cellular mediated autoimmune destruction of the β- cells of 
the pancreas. Type-II occurs at past middle age and common disease, in this there is 
no destruction of β- cells. Type-II is 95% prevalence and type-I is 5% prevalence 
among diabetes (8).  
The world wide prevalence of diabetes in 2013 was approximately 6.6% and 
estimated to grow to 7.8% by 2030. In India diabetes was 5% prevalence in urban 
areas and 2.7% prevalence in rural areas. 50.8 million people were affected in 2013 
and also reported that in India 87 million people will be affected in 2030. (9) 
Gliclazide:- 
 Gliclazide is a second-generation hypoglycaemic sulfonyl urea that can 
acutely lowers the blood glucose level in humans by stimulating the release of insulin 
from pancreas and is typically prescribed to treat type-II diabetes mellitus. The drug is 
selected as model for designing controlled release because of its short biological half-
life (3.4±0.7 h) necessitates that it can be administered 2 or 3 doses with 2 to 8 mg per 
day, and is easily absorbed from GIT. (10) 
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3. REVIEW OF LETERATURE 
  Diabetes is  a condition in which pancreatic beta cells does not produce 
insulin or impaired release of insulin due to inadequate or defective insulin receptors, 
and it also developed if insulin is not utilized by body cells.  
It is also a disorder of carbohydrate, protein and fat metabolism results an 
imbalance between insulin ability and insulin need. A person with uncontrolled 
diabetes is unable to transport glucose in to fat and muscle cells, as a result, the body 
cells are starved and the breakdown of fat and protein is increased. (11) 
 It is characterized by varying or persistent hyper glycaemia and glucosuria, 
hyper lipedimia, negative nitrogen balance. Polyurea (frequent urination) and 
polyphagia (increased hunger) are symptoms of diabetes. (12) 
TYPES OF DIABETES (13) 
                                          1) TYPE-I DIABTES (IDDM) 
                                          2) TYPE-II DIABETS (NIIDM) 
Type-I Diabetes:-  
 Type-I diabetes is also called as insulin dependent diabetes mellitus (IDDM), 
which accounts for only 5-10% of peoples with diabetes mellitus have this type of 
diabetes. It is characterized by destruction of pancreatic beta cells that means absolute 
lack of insulin, an elevated body glucose, and break down of body fats and proteins  
It is sub divided into two types: 
 Type IA:  Immune mediated diabetes. 
 Type IB:  Idiopathic diabetes. 
Type IA:  95% of type-I diabetes having Type IA. It is characterized by auto immune 
destruction of beta cells. This type is also called juvenile diabetes; occur more 
commonly in young people but may occurs at any age. 
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Type IB:  Only a small number of people with type-1 diabetes fall into this category. 
It is strongly inherited. People with this have episodic ketoacidosis due to varying 
degree of insulin deficiency with periods of absolute insulin deficiency that may come 
and go.  
Type-II Diabetes:- 
 Type-II diabetes is also called as non insulin independent diabetes (NIIDM). 
This was previously called “adult-onset diabetes” because in the past it was usually 
discovered after 40 years age. However, with increasing levels of obesity and 
sedentary lifestyle, this disorder is sometimes found even in children's so the term 
“adult-onset” is no longer used. (11).90-95% of diabetes comes under this category. 
In this type of diabetes, either the pancreas produce reduced amount of insulin, or 
body cells do not respond to insulin, sometimes both. They having insulin resistance 
and usually have relative (rather than absolute) insulin deficiency. They don't need 
insulin treatment to survive.  
 There are probably many different causes of this form of diabetes. Although 
the specific etiologies are not known, autoimmune destruction of β-cells does not 
occur. Most patients with this form of diabetes are obese, and obesity itself causes 
some degree of insulin resistance. Patients who are not obese by traditional weight 
criteria may have an increased percentage of body fat distributed predominantly in the 
abdominal region.  
 There are other less common types of diabetes called gestational diabetes, 
prediabetes.  
Gestational diabetes (14) 
 Pregnant women who have never had diabetes before but having high blood 
glucose levels during pregnancy are said to have gestational diabetes. Based on 
recently announced diagnostic criteria for gestational diabetes, it is estimated that 
gestational diabetes affects 18% of pregnancies. The exact cause for this is not 
known. This may lead to complications during pregnancy, labour and delivery. 
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Pre diabetes (15) 
 When a person's glucose level in the blood is above normal limits, but it is not 
enough for yielding results in a diabetes test, the condition is called pre-diabetes. 
Damage to heart and circulatory system can occur during this stage also without 
getting diagnosed with diabetes. If the patient takes precautionary measures for the 
control of blood sugar level, then he can prevent or delay the onset of type-II diabetes.  
DIAGNOSING DIABETES (16) 
Diabetes can be diagnosed in one of three ways: 
 Symptoms of diabetes (polyuria, polydipsia, unexplained weight loss) and 
casual plasma glucose (any time of day, regardless of fasting status) of ≥200 
mg/dL 
 Fasting plasma glucose (after 8 hours or longer of fasting) that is ≥126 mg/dL 
 Plasma glucose ≥200 mg/dL 2 hours after ingestion of 75-g oral glucose (2-
hour oral glucose tolerance test) 
                                                       Table- 1 
DIAGNOSIS 
 
FASTING 
PLASMA 
GLUCOSE 
2-HOUR ORAL 
GLUCOSE 
TOLERANCE TEST No diabetes 
 
<100 mg/dL 
 
<140 mg/dL 
 
Pre diabetes 
 
100–125 mg/dL 
 
140–199 mg/dL 
 
Diabetes 
 
≥126 mg/dL 
 
≥200 mg/dL 
 
 
CAUSE OF DIABETES MELLITUS(17) 
 The reason differs for people with type-I diabetes and those with type-II 
diabetes. However, the exact mechanisms for development of both diseases are still 
unknown. 
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Type-I diabetes causes:- 
 Type-1 diabetes usually occurs as a result of the body's immune system 
attacking the beta cells of the pancreas by mistake.  
 This is known as an auto-immune reaction. The immune system destroys or 
damages the pancreatic cells preventing the production of insulin. The reason 
why the immune system acts this way is not known exactly. 
 There is a genetic risk factor for type-1 diabetes, meaning people who have a 
family history of diabetes mellitus are more likely to develop an auto-immune 
reaction.  
 Another known cause of type- 1diabetes is a rare condition called pancreatitis, 
which causes pancreas to become inflamed, resulting in severe damage to the 
insulin-producing cells. 
Type-II diabetes causes:- 
 Type-II diabetes occurs when the pancreas does not produce enough insulin to 
take glucose out of blood and into the body’s cells, or when the cells develop 
resistance to insulin. Although the exact cause of type-II diabetes is not fully 
understood, there are many factors that increase the risk of developing the condition.   
These include:  
Being overweight or obese: 
Type-II diabetes is often linked to obesity, as excess body fat increases the risk 
of the body’s cells becoming less responsive to the effects of insulin. 80% of people 
who develop type-II diabetes are overweight or obese, have a large waist, and have an 
inactive lifestyle. 
Ethnic origin: 
People of certain ethnicities are more at risk of developing type-II diabetes 
than others. For instance, people of African-Caribbean or South Asian origin and 
living in the UK are at least five times more likely to develop type-2 diabetes than a 
person who is white.  
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Age: 
It is largely based on the fact that people usually become less active and gain 
weight as they grow older. Type-II diabetes is common in people who are over 40 
years old. So it is sometimes referred to as maturity onset diabetes. However, in 
recent years an increasing number of young adults and children have been diagnosed 
with the disease. 
Genetic factors: 
Type-II diabetes more likely to develop if one has a close relative such as a 
parent or sibling who has the disorder.  
Pre-diabetes:  
People having pre-diabetes may suffer from impaired glucose tolerance (IGT) 
or impaired fasting glycaemia (IFG). Both these conditions can develop into type-II 
diabetes if left untreated.   
DIABETES SYMPTOMS(18) 
 The symptoms of diabetes mellitus are generally the same for type-I and type-
II diabetes, but in type-I diabetes, these symptoms can develop very quickly compared 
to type-II diabetes. 
The three main symptoms of diabetes are 
 Polyuria (the need to urinate frequently) 
 Polydipsia (increased thirst and fluid intake) 
 Polyphagia (increased appetite)  
Other less severe symptoms of diabetes can include: 
 Extreme tiredness (fatigue) 
 Unexplained loss of weight and muscle bulk 
 Itchy skin or yeast infections 
 Blurred vision  
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 Cuts or sores that take a long time to heal  
 Tingling or numbness in hands or feet  
Nausea, vomiting, temperature or stomach pains may also accompany some of these 
symptoms in the sudden onset of type-I diabetes. 
DIABETES RISKS:- 
  If diabetes is not controlled, it will cause serious health problems which 
include cardiovascular disease, chronic renal failure, retinal damage, nerve damage, 
impotence and gangrene with risk of amputation of toes, feet, and even legs.  
Chronic complications:- 
Eye Complications: Diabetic retinopathy, cataracts and glaucoma are also more   
common among diabetics. 
Kidney damage: Kidney damage from diabetes is called diabetic nephropathy. 
Nerve damage: Nerve damage from diabetes is called diabetic neuropathy.  
Acute complications:- 
Diabetic ketoacidosis :  
Diabetic ketoacidosis is caused by the buildup of acid in blood. Symptoms 
include nausea, vomiting, and abdominal pain. Without prompt medical treatment, 
patients can rapidly go into shock, coma, and even death.  
Hyperosmolar state: This condition can lead to coma (hyperosmolar coma). A 
hyperosmolar coma usually occurs in elderly patients with type 2 diabetes. Like 
diabetic ketoacidosis, a hyperosmolar coma is a medical emergency. 
 Blood glucose is essential for the proper functioning of brain cells. Therefore, 
low blood sugar can lead to central nervous system symptoms such as: 
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 Dizziness 
 Confusion 
 Weakness  
 Tremors  
TREATMENT 
 There is no cure for diabetes, regular treatment can help to control this life-
long disease and decrease the risk of other health conditions developing later in life. 
The type of treatment require depends on the type of diabetes and lifestyle, although it 
generally involves taking medication, monitoring blood glucose levels, exercising on 
a regular basis and making changes to diet.  
TREATMENT OF TYPE-I DIABETES(19) 
Insulin treatments: 
 Type-I diabetes has regular insulin treatment. There are many types of insulin 
some are designed to work very quickly but for a short amount of time, while others 
are designed to last up to a whole day and various methods of taking insulin 
treatment.   
These include: 
Insulin injections:-  
 Daily insulin injections are usually required for people with type-I diabetes. 
There are two main devices for injecting insulin syringe and injection pen also called 
as insulin pen. 
Insulin pump therapy:- 
 It is an alternative to insulin injections. It involves the use of small insulin 
pump that allows insulin to flow into the bloodstream (through a needle which is 
inserted under the skin of stomach, hips, buttocks, thighs or arms) in controlled 
manner. This replaces the use of injections, but it will need to keep a close eye on 
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blood glucose levels to ensure the receiving right amount of insulin. These are 
accurate, precise and flexible, although they can be hard to access and expensive.  
Insulin jet injectors:- 
 Insulin jet injectors are a relatively new development in diabetes management 
that delivers insulin into the body without the use of a needle, making them ideal for 
people who have needle phobia. This type of device works by sending a fine spray of 
insulin through the skin at a very fast speed using a high-pressure air current. They 
can be used on the stomach, buttocks or thighs.  
OTHER TREATMENTS: 
 Type-I diabetes may also take a number of medicines to reduce the risk of 
developing serious complication such as heart disease, stroke and kidney disease. 
Also need a flu vaccine every year, and a one-off vaccination that protects against 
some forms of pneumonia and meningitis. 
TREATMENT OF TYPE-II DIABETES:- 
 Treatment of type-II diabetes typically includes taking healthy diet, regular 
exercise and losing weight if overweight or obese and home blood glucose testing. 
These help to regulate blood glucose levels. However, it is found that diet and 
exercise are not enough to keep blood glucose at a healthy level, oral medication is 
required.  
Medicines used to treat type-II diabetes :- 
 Sulfonylureas: These drugs stimulate the pancreas to make more 
insulin. 
 Biguanides: These agents decrease the amount of glucose produced by 
the liver. 
 Alpha-glucosidase inhibitors: These agents slow absorption of the 
starches a person eats. This slows down glucose production. 
 Thiazolidinediones: These agents increase sensitivity to insulin. 
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 Meglitinides: These agents stimulate the pancreas to make more 
insulin. 
 D-phenylalanine derivatives: These agents stimulate the pancreas to 
produce more insulin more quickly. 
 Amylin synthetic derivatives: Amylin is a naturally occurring hormone 
secreted by the pancreas along with insulin. And helps to reduce 
fluctuation of blood sugar levels throughout the day, and improves 
haemoglobin A1C levels. 
 Incretin mimetics: Incretin mimetics promote insulin secretion by the 
pancreas and mimics other blood sugar level lowering actions that 
naturally occur in the body.  
 Insulins: Different types of insulin are available and categorized 
according to their onset of action and duration.  
Examples of rapid-acting insulins  
  Regular insulin (Humulin R, Novolin R) 
  Insulin lispro (Humalog) 
  Insulin aspart (Novolog) 
  Insulin glulisine (Apidra) 
  Prompt insulin zinc (Semilente, slightly slower acting) 
 Examples of intermediate-acting insulins  
  Isophane insulin, Neutral protamine hagedorn (NPH) (Humulin N,  
            Novolin N) 
  Insulin zinc (Lente)  
Examples of long-acting insulins  
  Extended insulin zinc insulin (Ultralente) 
  Insulin glargine (Lantus) 
  Insulin detemir (Levemir) 
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PREVENTION:- 
Diabetes can be prevented by changing a person's diet and by having proper 
exercise. Taking healthy diet, regular physical activity will help to prevent or delay 
type-II diabetes it is not yet known how to prevent type-I diabetes. Type-II diabetes, 
however, can be prevented in some cases.  
 Control weight to normal or near-normal levels by eating a healthy 
low-fat, high-fibre diet.  
 Regular exercise is crucial to the prevention of type-I diabetes.  
 Keep alcohol consumption low.  
 Quit smoking.  
 If a person has high blood fat levels or high blood pressure, take all 
medications as directed.  
 Lifestyle modifications and certain medications can be used in people 
with prediabetes to prevent progression to diabetes.  
 Diabetic patient should focus on preventing the complications, which 
can cause serious disabilities such as blindness, kidney failure 
requiring dialysis, amputation, or even death.  
 Drink an adequate amount of water and avoid consuming too much 
salt.  
 The skin should be taken care and keep it supple and hydrated to avoid 
sores and cracks that can become severely infected.  
 Brush and floss the teeth every day. See a dentist regularly to prevent 
gum disease.  
 The feet should be washed and examined daily, looking for small cuts, 
sores, or blisters that may cause problems later. The toenails should be 
filed rather than cut to avoid damaging the surrounding skin.  
 
• DIABETES CONTROL 
 Avoid sweets completely.  
 Fried and fatty foods should be minimized.  
 Insulin will work properly if overweight is reduced.  
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 Foods containing more fibre should be taken. This will help to reduce 
the absorption of glucose into the blood stream, thereby reducing the 
sugar level in the blood.  
 Consumption of egg yolk, mutton and beef should be reduced. Take 
fish and chicken without skin instead.  
 Amount of oil used in a day should not exceed 4 teaspoons.  
 Avoid Vanaspathi and Margarine.  
 Avoid excessive eating.  
 Do not skip exercise.  
 Reduce stress and maintain good health. 
SULFONYLUREAS (20) 
 Sulphonyl ureas are oral hypoglycaemics, used in the treatment of type-II 
diabetes. These are rapidly absorbed after oral administration, onset of action is 1-2 
hours and peak reaches in 4-6 hours. They bind strongly to plasma albumin and 
execrated through urine. 
 They cross the placenta and stimulate beta-cells to release insulin, causing 
severe hypoglycaemia at the time of birth. Hence these are contraindicated in 
pregnancy. 
Pharmacology: 
Sulphonyl ureas stimulate beta-cells, effective only in the presence of 
functioning pancreas. The presence of at least 30% beta-cells is essential for their 
action. They are secretagogues. 
(i) Pancreatic effect: Stimulate pancreas to produce more insulin, and increase 
peripheral utilization of glucose. 
(ii) Extra pancreatic effect: - They inhibit gluconeogenesis in liver. 
(iii) They also produce post receptor intracellur beneficial effects, and lower the 
elevated free fatty acid levels. 
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GLICLAZIDE(21)  
 gliclazide  is an anti-diabetic drug comes under the category of second-
generation sulfonylurea, and is very potent. It acts as insulin sensitizer that has been 
widely used in management of NIDDM. Its half life is 5 hrs, more than 99% bind to 
plasma proteins, and is mainly excreted through urine remaining through faeces. 
gliclazide should be administered with breakfast or the first main meal. 
Recommended dose is minimum 2 mg to maximum 8 mg. 
    Like glyburide and glipizide, glimepiride is a "second-generation" 
sulfonylurea agent. gliclazide is used with diet to lower blood glucose by increasing 
the secretion of insulin from pancreas and increasing the sensitivity of peripheral 
tissues to insulin. 
Mechanism of action (22) 
The mechanism of action of gliclazide in lowering blood glucose appears to be 
dependent on stimulating the release of insulin from functioning pancreatic beta cells, 
and increasing sensitivity of peripheral tissues to insulin. gliclazide likely binds to 
ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing 
potassium conductance and causing depolarization of the membrane. Membrane 
depolarization stimulates calcium ion influx through voltage-sensitive calcium 
channels. This increase in intracellular calcium ion concentration induces the 
secretion of insulin. 
MICROSPHERES (23) 
  Novel drug delivery systems have several advantages over conventional multi 
dose therapy recent trends indicate that microparticulate drug delivery systems are 
especially suitable for achieving controlled or delayed release oral formulations with 
low risk of dose dumping, flexibility of blending to attain different release patterns as 
well as reproducible and short gastric residence time. The release of drug from 
microparticles depends on a variety of factors including the carrier used to form the 
microparticles and the amount of drug contained in them. Consequently, 
microparticulate drug delivery systems provide tremendous opportunities for 
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designing new controlled and delayed release oral formulations, thus extending the 
frontier of future pharmaceutical development. 
  One such approach is using microspheres as carriers for drugs. It is the reliable 
means to deliver the drug to the target site with specificity, if modified, and to 
maintain the desired concentration at the site of interest without untoward effects 
Microencapsulation is a process whereby small discrete solid particles or small liquid 
droplets are surrounded and enclosed by an intact shell. Microencapsulation is used to 
modify and delayed drug release form pharmaceutical dosage forms. A well designed 
controlled drug delivery system can overcome some of the problems of conventional 
therapy and enhance the therapeutic efficacy of a particular drug. It is the reliable 
means to deliver the drug to the target site with specificity, if modified, and to 
maintain the desired concentration at the site of interest without untoward effects. 
Microspheres received much attention not only for prolonged release, but also for 
targeting of drugs.  
 Micro-particles are the polymeric entities falling in the range of 1-1000µm. 
Micro-particles covering two types of the forms as follows: 
(1) Microencapsules : micrometric reservoir systems.  
(2) Microspheres      :  micrometric matrix systems. 
 Microspheres are matrix systems and essentially spherical in shape, whereas 
microcapsules may be spherical or non-spherical in shape. 
Drug loading and drug release kinetics (24) 
 The active components are loaded over the microspheres principally using two 
methods, i.e. during the preparation of the microspheres or after the formation of the 
microspheres by incubating them with the drug/protein. The active component can be 
loaded by means of the physical entrapment, chemical linkage and surface adsorption. 
The entrapment largely depends on the method of preparation and nature of the drug 
or polymer. 
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  Maximum loading can be achieved by incorporating the drug during the time 
of preparation but it may get affected by many other process variables such as method 
of preparation, presence of additives (e.g. cross linking agent, surfactant stabilizers, 
etc.) heat of Polymerization, agitation intensity, etc. Release of the active constituent 
is an important consideration in case of microspheres. The release profile from the 
microspheres depends on the nature of the polymer used in the preparation as well as 
on the nature of the active drug.  
 The release of drug from both biodegradable as well as non-biodegradable 
microspheres is influenced by structure or micro-morphology of the carrier and the 
properties of the polymer itself. The drugs could be released through the microspheres 
by any of the three methods, first is the osmotically driven burst mechanism, second 
by pore diffusion mechanism, and third by erosion or the degradation of the polymer. 
In osmotically driven burst mechanism, water diffuse into the core through 
biodegradable or non-biodegradable coating, creating sufficient pressure that ruptures 
the membrane.(25)  
          The burst effect is mainly controlled by three factors the 
macromolecule/polymer ratio, particle size of the dispersed macromolecule and the 
particle size of the microspheres. The pore diffusion method is named so because as 
penetrating water front continue to diffuse towards the core. The polymer erosion, i.e. 
loss of polymer is accompanied by accumulation of the monomer in the release 
medium. The erosion of the polymer begins with the changes in the microstructure of 
the carrier as water penetrates within it leading to the plasticization of the matrix. 
 Drug release from the non-biodegradable type of polymers can be understood 
by considering the geometry of the carrier. The geometry of the carrier, i.e. whether it 
is reservoir type where the drug is present as core, or matrix type in which drug is 
dispersed throughout the carrier, governs overall release profile of the drug or active 
ingredients.(26)
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3.1 REVIEW OF RELEVENT WORK 
Satish V et.al (27)  in the present study was microspheres of Pioglitazone 
hydrochloride were prepared for the prolongation of gastric residence time. The 
microspheres were prepared by emulsion solvent diffusion-evaporation method using 
ethyl cellulose and HPMC K100M. A full factorial design was applied to optimize the 
formulation. Results showed that formed microsphere exhibited smooth surfaces with 
good flow and packing properties, prolonged sustained drug release, remained buoyant 
for more than 10 hrs, high entrapment efficiency up to 97%w/w. Scanning electron 
microscopy confirmed the hollow structure with particle size in the order of 190 µm. The 
studies revealed that increase in concentration of hydrophilic polymer (HPMC) increased 
the drug release from the microspheres 
Shiv Shankar Hardenia  et. al (28) In the present research work, ethylcellulose 
microspheres containing ciprofloxacin were prepared and evaluated for in-vitro 
performance of ciprofloxacin. Ciprofloxacin microspheres containing ethylcellulose were 
prepared by emulsion solvent diffusion evaporation method. The surface morphological 
characteristics of ethylcellulose microspheres were investigated using scanning electron 
microscopy. The polymer ratio, stirring speed and the temperature affected the particle 
size, shape and surface morphology of the microspheres. The in-vitro drug release was 
carried out using USP paddle type dissolution rate test apparatus in 0.1N Hcl dissolution 
medium at 291nm. It was found that drug release from the formulations was different at 
different concentrations of polymers and different RPM and temperature. The best 
cumulative release was achieved after 24 hrs i.e. 91.6%. The Mucoadhesive property of 
the ethylcellulose microspheres was evaluated by in-vitro wash off test. The microspheres 
exhibited 75% mucoadhesion and showed good drug entrapment efficiency. By, above 
results it was concluded that ethylcellulose microspheres showed reproducible results, 
with good Mucoadhesive properties and good surface morphology. 
Syed Shariff Miyan et al  (29)  In the present investigation was to prepare fast 
dissolving tablets of a hypoglycemic drug Gliclazide. The solubility of poorly soluble 
drug was enhanced by preparing solid dispersions of the drug with PEG 6000 in various 
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concentrations. The optimized solid dispersions (Drug: PEG-6000, 1:2 ratio) were further 
kneaded with suitable proportions of superdisintegrants such as; Crosscarmellose, 
Sodium starch glycolate and Cross povidone. Fast dissolving tablets of Gliclazide was 
prepared by direct compression method. The pre-compressive parameters for the blends 
and post-compressive parameters for the prepared tablets were evaluated. All 
formulations showed desired pre and post-compressive characteristics. Short term 
accelerated stability study was performed for optimized formulation and found no 
evidence of physical and chemical changes. FT IR study showed no evidence of drug 
excipient interaction. The optimized formulation was found to be FDT6. It was concluded 
that fast dissolving tablets of Gliclazide can be prepared by solid dispersions of drug with 
PEG-6000 and combination of two super disintegrants provide complete and better 
dissolution within in shorter period of time. Hence effective diabetic treatment anywhere, 
and anytime particularly for geriatric, pediatric, mentally ill, bedridden and patients who 
do not have easy access to water .  
Richard C O'Briena et al (30) Diabetes is a state of increased oxidant stress and 
there is evidence that oxidation may play a role in the genesis of complications. 
Gliclazide, a sulfonylurea hypoglycemic drug, has been shown to possess free radical 
scavenging properties. This study examined the effects of in vitro supplementation with 
gliclazide and other sulfonylureas as on low-density lipoprotein (LDL) oxidation and the 
total plasma antioxidant capacity (TPAC). In a separate study, the effects of 10 months of 
oral gliclazide therapy on oxidative parameters were assessed in 44 type 2 diabetic 
patients. Gliclazide, but not glibenclamide, glimepiride, glipizide or tolbutamide, 
inhibited LDL oxidation and enhanced TPAC. With the addition of 1 µM gliclazide, 
oxidation lag time increased from 53.6±2.6 to 113.6±5.1 min (p<0.001), and TPAC 
increased from 1.09±0.11 to 1.23±0.11 mM (p<0.01). Administration of either modified 
release or standard gliclazide to type 2 diabetic patients resulted in a fall in 8-
isoprostanes, a marker of lipid oxidation, and an increase in the antioxidant parameters 
TPAC, SOD and thiols. These studies show that gliclazide possesses antioxidant 
properties that produce measurable clinical effects at therapeutic doses. 
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Jacob Shiny et al  (31) In the present study was to develop a novel 1 month depot 
paclitaxel (PTX) microspheres that give a sustained and complete drug release. PTX 
loaded microspheres were prepared by o/w emulsion solvent evaporation technique using 
the blends of poly(lactic-co-glycolic acid) (PLGA) 75/25, polycaprolactone 14,000 and 
polycaprolactone 80,000. Fourier transform infrared spectroscopy was used to investigate 
drug excipient compatibility. Compatible blends were used to prepare F1-F6 
microspheres, the process was characterised and the optimum formulation was selected 
based on the release. Optimised formulation was characterised for solid state of the drug 
using the differential scanning calorimetry (DSC) studies, surface morphology using the 
scanning electron microscopy (SEM), in vivo drug release, in vitro in vivo correlation 
(IVIVC) and anticancer activity. Anticancer activity of release medium was determined 
using the cell viability assay in Michigan Cancer Foundation (MCF-7) cell line. Blend of 
PLGA with polycaprolactone (Mwt 14,000) at a ratio of 1:1 (F5) resulted in complete 
release of the drug in a time frame of 30 days. F5 was considered as the optimised 
formulation. Incomplete release of the drug resulted from other formulations. The surface 
of the optimised formulation was smooth and the drug changed its solid state upon 
fabrication. The formulation also resulted in 1-month drug release in vivo. The released 
drug from F5 demonstrated anticancer activity for 1-month. Cell viability was reduced 
drastically with the release medium from F5 formulation. A 100% IVIVC was obtained 
with F5 formulation suggesting the authenticity of in vitro release, in vivo release and the 
use of the formulation in breast cancer.our study, it was concluded that with careful 
selection of different polymers and their combinations, PTX 1 month depot formulation 
with 100% drug release and that can be used in breast cancer was developed. 
Takeshi Morirero et al(32) Microspheres of biodegradable polymers were 
evaluated as a potential controlled-release drug-delivery system in the vitreous. The 
microspheres were prepared with polymers of poly(lactic acid) or co polymcrs of glycolic 
acid and lactic acid. The release of 5-fluorouracil (5-FU) from the microspheres was 
studied in vitro. Poly(lactic acid) microspheres released 70-85% of total 5-FU over 7 
days. Microspheres of polymers with a smaller molecular weight released the drug more 
rapidly. Co polymcr microspheres released 98% of 5-FU over 2 days. The rate of drug 
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release was controllable by changing the molecular weight of the polymers or using a 
matrix of copolymer. The intravitreal kinetics of the microspheres were studied in ten 
rabbits in vivo. A suspension of microspheres was injected into the vitreous cavity of five 
normal eyes and five vitrectomized eyes. By 48 ± 5.2 days after injection, the 
microspheres disappeared from the vitreous cavity in the five normal eyes. Clearance 
from the vitreous cavity was accelerated in the five rabbits that underwent vitrectomy (14 
± 2.4 days; P < 0.001). No difference was found in the b waves of electroretinograms 
before and after injection of the microspheres. The histologic study showed no abnormal 
findings as a result of the injection. These results suggested that microspheres of 
biodegradable polymers may be a potential delivery system for the controlled release of 
drugs in the vitreous. 
L.Sambath et al (33)  in the present study For a quality formulation, various 
formulation parameters that play a crucial role are aqueous solubility; stability at ambient 
temperature and humidity, photo-stability, compatibility with solvents etc. Among all 
these, Solubility is the most important property for developing formulations. The present 
study is an attempt to improve the solubility and dissolution rate using solid dispersion of 
a poorly soluble drug Gliclazide by using Soluplus as carrier material to enhance the 
solubility as well as dissolution rate. Four different formulations were prepared using hot 
melt extrusion technique in different ratios i.e., 1:1, 1:2, 1:3 and 1:4 were further 
characterized by FTIR, DSC, and XRD analysis. The results of FTIR revealed that no 
chemical interaction between the drug and the polymer exist. DSC studies showed that 
the drug was in amorphous state completely entrapped by the polymer. XRD studies 
showed decrease in the peak intensity or absence of peaks which indicated the amorphous 
nature of gliclazide in solid dispersions. All the formulations showed a marked increase 
in drug release with the increase in the concentration of soluplus when tested for their in 
vitro studies. Formulation SD4 showed the desired release with a cumulative release of 
95% in 50 mins when compared to the pure drug, Physical mixture. Hence, soluplus look 
to be a promising carrier to improve the solubility of poorly soluble dr. 
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NP Sapkal et al (34)  In the present study Gliclazide has been found to form 
inclusion complexes with β- cyclodextrin (β-CD) in solution and in solid state. The 
present study was undertaken to determine a suitable method for scaling up gliclazide-β-
CD inclusion complex formation and to evaluate the effect of some parameters on the 
efficiency of complexation. Method: The solid inclusion complexes of gliclazide and β-
cyclodextrin were prepared at a molar ratio of 1:1 and 1:2 by mixing, kneading, and 
coprecipitation methods both on small and large scales. The effect of parameters such as 
kneading time and temperature on complexation was also studied. Characterization was 
performed using infrared spectroscopy, X-ray diffractometry, and dissolution studies. In 
vitro release studies were carried out in phosphate buffer (pH 6.8). All the methods of 
preparation of complexes were found to be useful in increasing the solubility of gliclazide 
except mixing method where the rise in solubility was not significant. Both kneading and 
co-precipitation methods in 1:2 molar ratios were found to be equally effective in 
improving the solubility of gliclazide. The formation of inclusion complexes was evident 
in these formulations as shown by IR and XRD studies. But when carried out on a large 
scale, co-precipitation method was found to be more tedious and time-consuming than 
kneading method. Moreover percent recovery of complexes in the kneading method was 
found to be 98.76% as compared to 92.05% in case of co-precipitation method. Drug 
content studies, IR spectroscopic studies, X-Ray diffractometry studies and in vitro 
dissolution study data indicated that inclusion complexes prepared by kneading method 
in 1:2 molar ratios were suitable for improving the solubility of gliclazide. The same 
formulation was prepared at large scale and optimum formulation conditions were 
establishe 
Sudarsan Biswal et al (35) in the present study Gliclazide is an anti-diabetic drug 
that is poorly soluble in water. This paper describes an approach to improve the 
dissolution rate of gliclazide by using solid dispersions (SDs) in polyethylene glycol 4000 
(PEG 4000). The phase-solubility behavior of gliclazide in the presence of various 
concentrations of PEG 4000 in 0.1 N HCl at 37 °C was obtained. The solubility of 
gliclazide increased with increasing amounts of PEG 4000 in water. The Gibbs free 
energy (∆Gotr) values were all negative. The solid dispersions were prepared with a 
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solvent-melting method using different concentrations of PEG 4000. X-ray diffraction, 
infrared spectroscopy, and DSC were used to examine the physicochemical 
characteristics of solid dispersions of gliclazide and PEG. The dissolution rate of 
gliclazide in SDs with PEG 4000 was enhanced. The FTIR spectroscopic studies showed 
the presence of intermolecular hydrogen bonding between gliclazide and PEG 4000 in the 
solid state. The DSC and XRD studies indicate the amorphous and microcrystalline states 
of gliclazide in SDs with PEG 4000. 
Mahendra Labana et al (36) In the present work, modified release gliclazide once 
a daily tablet were designed for non-insulin dependent diabetes for better patient 
compliance by direct compression method,  HPMC was used as polymer, Dibasic 
calcium phosphate and Maltodextrin as binder for direct compression. Estimation of MR 
Gliclazide in the prepared tablet formulations was carried out at 226 nm in phosphate 
buffer pH 7.4. The prepared formulations were further evaluated for hardness, friability, 
drug content uniformity, in vitro dissolution time. for in vitro drug release pattern in pH 
7.4phosphate buffer and short-term stability (at 40ºC/ 75% RH for 3 months) and drug 
excipient interaction (IR spectroscopy) were studied. Short-term stability studies on the 
promising formulations indicated that there are no significant changes in drug content and 
in vitro dissolution time. 
                Sharmi islam  et al (37) In this study solid dispersion (SDs) of gliclazide were 
prepared by solvent evaporation technique using poloxamer 407 as carrier. Drug carrier 
weight ratio were 1:1, 1:3 and 1:5. Physical mixtures of the same ratio were also prepared 
for comparison. The solid dispersions were investigated for drug loading and dissolution 
behavior and were found effective to enhance the solubility of gliclazide in dissolution 
medium significantly. Evaluation of the properties of the SDs was also performed by 
using Fourier-transform infrared (FTIR) spectroscopy and X-ray diffraction (XRD) 
studies. The FTIR spectroscopic studies showed the stability of gliclazide and absence of 
interaction between gliclazide and poloxomer 407. The XRD studies indicated the 
amorphous state of gliclazide in SDs. Dissolution data of SDs were compared by using 
both model dependant and model independent techniques. No significant difference in % 
DE (dissolution efficiency) was found among the SDs. But the drug release rate from 
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SDs differs from that of physical mixture. So, solid dispersion technique may be an 
effective way to enhance dissolution rate of gliclazide. 
Sharma GS et al (38) in the presents tudy was studied   Gliclazide is a second 
generation sulphonyl urea with poor aqueous solubility. The aim of the present 
investigation is to increase the aqueous solubility of Gliclazide (Glz) by using Hydroxy 
Propyl β-Cyclodextrin (HPβ-CD). Solubility studies for Glz and HPβ-CD were 
performed which reveals that, it follows AL type profile, the solubility of Gliclazide is 
proportionally increases as the concentration of HPβ-CD increases. Glz- HPβ-CD 
complexes were prepared in different ratios (1:0.5, 1:0.75, 1:1 molar ratios ) by using 
different preparation techniques (physical mixture, kneading method and solvent 
evaporation method). FTIR studies were conducted for all the prepared complexes and 
the results concluded that there were no interactions between Glz and HPβ-CD. 
Dissolution studies were performed for all the prepared complexes in phosphate buffer of 
pH 7.4. The results conclude that complex prepared by solvent evaporation method at 1:1 
molar ratio has faster dissolution rate when compared with all the other complexes. 
S Biswal et al (39)    The aim of the present study was to characterise gliclazide 
solid dispersions (SDs) preparedwith polyethylene glycol (PEG) 8000 and compare them 
with SDs in PEG 6000. Methods: Gliclazide SDs containing varying concentrations of 
PEG 8000 were prepared using the fusion – solvent technique, and their phase solubility 
behavior and dissolution in 0.1N HCl were assessed at 37 oC. The physical state of, and 
gliclazide-PEG interactions in, SDs and physical mixtures prepared in ratios of 1:1, 1:2 
and 1:5 (gliclazide: PEG 8000), respectively, were characterized by x-ray diffraction 
(XRD), Fourier-transform infrared (FTIR) spectroscopy and differential scanning 
calorimetry (DSC). Results: The solubility of gliclazide increased with increasing amount 
of PEG 8000 in aqueous medium. Gibbs free energy (Go tr) values were all negative, 
indicating the spontaneous nature of gliclazide solubilisation. Dissolution studies 
indicated a significant increase in the dissolution of gliclazide when dispersed in PEG 
8000. FTIR analysis demonstrated the absence of well-defined gliclazide - PEG 8000 
chemical interaction while DSC and XRD studies indicated the amorphous 
/microcrystalline state of gliclazide in the SDs. Conclusion: In both solid dispersions and 
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physical mixture, PEG 8000 increases the solubility and dissolution rate of gliclazide. 
The increased dissolution rate of gliclazide may be due to the formation of microcrystals, 
increased wettability and dispersibility in systems containing PEG 8000. 
Pei-Heng Lai  et al (40) To study the potential of Poloxamer 407 as the 
thermogelling and mucoadhesive polymer for the development of a site-targeting delivery 
system to enhance the delivery of anti-cancer drugs to the colorectal cancer cells. 
Methods: Poloxamer 407 was completely dispersed, with a continuous agitation, in the 
distilled water. The temperature was then cooled down to 4., while the agitation 
continuous, until a clear solution is produced. The cytotoxicity of Poloxamer 407 solution 
was performed and analyzed by MTT, while its mucoadhesive strength and rheological 
properties were also measured, as a function of Poloxamer concentrations. Results: In 
order to confirm whether or not Poloxamer 407 is biocompatible to the target cells, its 
cytotoxicity against the colorectal cancer was evaluated and the results suggested that it is 
nontoxic to 5 primary colon cancer cells up to a concentration of 150mg/mL (Fig. 1). The 
gelation temperature-concentration profile in Fig. 2 indicates that Poloxamer 407. The 
results in Table 1 indicate that the mucoadhesive strengths of Poloxamer 407 show a 
temperature-dependent increase, which appears to be related to the increment in the 
dynamic viscosity and elastic modulus of the polymer. Conclusion: Poloxamer 407 could 
be a potential thermogelling and mucoadhesive polymer for the development of a site-
targeting colorectal DDS.  
T.s.keerthi et al (41) in the Present investigation describes preparation of 
microspheres by solvent evaporation followed by in vitro characterization of 
microspheres to evaluate the effect of method of preparation on physical properties and 
drug release profile of microspheres. The microspheres were found to be discrete, 
spherical with free flowing properties. The morphology (Scanning Electron Microscopy), 
particle size distribution, entrapment efficiency and their release profiles were 
investigated. The yield was found to be maximum in case of solvent evaporation method. 
The microsphere prepared by solvent evaporation method was found in ranges of 250-50 
µm, respectively. The microspheres formulation prepared by solvent evaporation method 
the drug carrier interactions were investigated in solid state by Fourier Transform 
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Infrared (FT-IR) spectroscopy study. In vitro drug release rate for A microsphere was 
found to be sustained over 12 hours. Hence, it can be concluded that the Formulation 
prepared by solvent evaporation method, has potential to deliver Losartan Potassium in a 
controlled manner in a regular fashion over extended period of time in Comparison to all 
other formulations and can be adopted for a successful oral delivery of Losartan 
potassium for safe management of hypertension.  
Meral Yüce  Et Al (42) In the present study was Indomethacin-loaded 
microspheres of ethylcellulose were prepared by the emulsion solvent evaporation 
technique. The aim of this work was to investigate the influence of process variation 
inpolymer type via viscosity grades of ethylcellulose N10 and N100, drug to polymer 
ratio, stirring rate of the propeller and surfactant type on the micromeritic properties of 
microspheres such as particle size distribution, bulk and tapped density, surface 
topography, tangent of angle of repose, compressibility index, Hausner ratio and flow 
rates. All microspheres presented a narrow particle size distribution and good flow 
characters according to USP 28-NF 23 criteria, besides microspheres were more spherical 
in shape in their manufacture with ethylcellulose N100 and higher ratio of both polymers. 
Thus, in the case of ethylcellulose, the viscosity and ratio of the polymer in dispersion 
medium were found to be the controlling factors of drug release. Ethylcellulose N10 and 
N100 membrane materials indicated difference in release patterns of microspheres. 
Microspheres exhibited lower burst effect with decreased drug release rate, when the 
drug was incorporated with ethylcellulose N100 and higher ratio of each polymer. 
Therefore, indomethacin release from ethylcellulose microspheres could not be evaluated 
by any of the kinetic models. 
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4. AIM AND OBJECTIVE 
Gliclazide is an anti-diabetic drug comes under second generation sulfonylureas, 
and is a good insulin sensitizer that has been widely used in management of NIDDM. It’s 
half life is 5hours, more than 99% bind to plasma proteins and is absorbed completely 
from the entire GIT. 
 Since, Gliclazide is well absorbed from GIT controlled release formulation that 
retained in the GIT will be beneficial for effectively controlling diabetes. Several 
methods have been reported which can be used to retain the dosage form in the GIT, 
which results in the spreading the drug slowly over the absorptive surface in the GIT. A 
gastro retentive dosage form is one approach that will release the drug over a prolonged 
period of time in GIT thus enhancing the opportunity for absorption of drug. Considering 
the above factors, the present work is aimed to formulate and evaluate the Gliclazide 
microspheres for controlled release in the GIT. 
The objective of the present research work would be:- 
To develop suitable formula and procedure for the manufacturing of Gliclazide 
microspheres 
 To study the effect of  polymer concentrations. 
 To evaluate the different parameters of  microspheres. 
 To perform in vitro drug release study. 
 To know the release kinetics. 
 
 
 
 
 
 
29 
 
5. PLAN OF THE WORK 
The present  work  was  carried  out  to  design  and  evaluate  the   microspheres  
of gliclazide.  
The study is carried out in the following sequences: 
1) Preformulation studies 
 Compatibility study using differential scanning calorimetry.  
 Compatibility study using FT-IR spectrophotometry. 
2) Preparation of standard curve of gliclazide  in pH7.4 buffer . 
3) Formulation of gliclazide microspheres Using poloxemer  
4)  Evaluation of the prepared  microspheres of  Gliclazide. 
 Particle size. 
 Encapsulation efficiency. 
 Drug content. 
 Percentage yield. 
 Shape and surface characterization of prepared microspheres (SEM).  
 In-vitro dissolution studies. 
5) Application of drug release kinetics. 
 
 
 
 
6.1. DRUG PROFILE (43,44
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Molecular Formula                      
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6. PROFILES 
)
 
Gliclazid, gliclazida, gliclazidum.  
:Anti diabetic drug. 
   : Benzenesulfonamide, N-   [[(hexahydrocyclopenta[c]  
pyrrol-  2(1H)-yl)amino]carbonyl]-
: 
 
:   C15H21N3O3S. 
:   323.42 
:    180-182 0  C 
:   Gliclazide is white powder. 
:   Class II. 
 
 
4-methyl. 
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Solubility                                      :   Gliclazide is freely soluble in dimethyl                    
                                                         formamide; slightly soluble in methanol    
                                                         sparingly soluble in  methylene chloride;    
                                                         practically insoluble in water. It also dissolves  
                                                         in dilute alkali hydroxides and in dilute acids.                                                
Dose                                             :    The usual maintenance dose is 1 to 4 mg,   
                                                         The maximum recommended dose is 8 mg.  
PHARMACOKINETICS 
Absorption 
Completely (100%) absorbed following oral administration. Food intake has no 
relevant influence on absorption, only absorption rate is slightly diminished. 
Distribution 
Plasma protein binding is greater than 99%.  
Volume of Distribution: 
1) Volume of Distribution after oral administration was19.8 to 37.1 L. 
2) Volume of Distribution after intravenous administration was 9 L. 
Metabolism 
Gliclazide undergoes hepatic metabolism. Following either an intravenous or 
oral dose, gliclazide is completely metabolized by oxidative biotransformation to a 
major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic 
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cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative 
(M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately 
one third of the pharmacologic activity of its parent in an animal model. However, 
whether the glucose-lowering effect of M1 is clinically significant and is not clear  
Excretion 
     Gliclazide is mainly excreted through kidney.  Most of a dose of Gliclazide is 
excreted in the urine as metabolites (up to 60%). No parent compound is recovered 
unchanged. About 40% is excreted through Faces. 
Gliclazide, clearance increases with decreasing renal function probably due to 
more unbound drug with hypo albuminemia. The clearance of both metabolites decreased 
with worsening renal function. Patients with diabetes mellitus and creatinine clearance 
(CrCL) less than 20 ml/min to more than 50 ml/min were treated with gliclazide 1 to 8 
mg/day for 3 months. The dosage was adjusted based on blood glucose response. 
Total Body Clearance is 48 to 53 ml/min; and elimination half-life is 5 to 8 hrs 
after oral administration.        
CLINICAL PHARMACOLOGY:- 
Mechanism of action 
The mechanism of action of Gliclazide in lowering blood glucose appears to be 
dependent on stimulating the release of insulin from functioning pancreatic beta cells, 
and increasing sensitivity of peripheral tissues to insulin. Gliclazide likely binds to ATP-
sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium 
conductance and causing depolarization of the membrane. Membrane depolarization 
stimulates calcium ion influx through voltage-sensitive calcium channels. This increase 
intracellular calcium ion concentration induces the secretion of insulin. 
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PHARMACODYNAMICS 
Drug Interactions 
Acebutolol :  
Acebutolol is Beta blocking agents, administration of this with Gliclazide 
produce: hypoglycemia, hyperglycemia, or hypertension. 
NSAID: 
Concomitant use of an NSAID and a sulfonylurea suggest an increased risk of 
hypoglycemia may occur.  
Example: - Aceclofenac, Acemetacin   
Over dosage 
• After ingestion of an over dosage hypoglycaemia may occur, lasting from 12 to 
72 hour, and is accompanied by neurological symptoms like restlessness, tremor, 
visual disturbances, co-ordination problems, sleepiness, coma and convulsions. 
• Nausea, vomiting and epigastric pain may occur. 
Contra indications: 
Gliclazide is contraindicated in patients with the following conditions:- 
• Hypersensitivity to glimepiride, other sulfonylureas or sulfonamides  
• Insulin dependent diabetes  
• Diabetic coma  
• Ketoacidosis   
• Pregnancy and lactation 
• Severe renal or hepatic function disorders. In case of severe renal or hepatic 
function disorders, a changeover to insulin is required. 
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Adverse effects: 
• Asthma 
• Blurred vision 
• Cholestasis 
• Hepatic porphyria 
• Hepatitis 
• Hyponatremia 
• Hypoglycaemia 
• Photosensitivity 
• Diarrhea, Nausea, Vomiting, and Abdominal pain 
Storage                                           :  It should be stored in dry place at below 250C. 
Use                                                  :  Used in the treatment of type-II diabetes 
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6.2 POLYMER PROFILE (45) 
POLOXIMER:-   
USP                                                 :  POLOXIMER 407 
Synonyms                                       :  Poloxalkol ;Lutrol ;Monolan; pluronic. 
Chemical name                               :  α-hydro-ώ-hydroxy 
    poly(oxyethylene)   poly(oxypropylene)  
    poly(oxyethylene)                                                                          
Empirical Formula                          :   poloximer polyols are a series of closely related  
   Block copolymers of ethylene oxide and       
   propylene oxide   
Molecular weight                          :   Molecular weight is approximately  
          (9840-14600 Dalton) 
Chemical structure              :           
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Functional category                  :  dispersing agent, emulsifying and coemulsifuing  
 agent, solubilizing agent ,tablet lubricant. 
Description                                  
           color                          :  white color 
          Physical form        :  waxy and free flowing prilled granules.    
           Taste           :  tasteless 
           Odour      :  odorless     
Typical properties :- 
 Density                                              :   1.06  g/ cm3 at25° c    
Viscosity                                             :   1000 mPa s (1000cp) as a meltn at a77 °c 
Methoxyl Content                               :   19-24%.      
Moisture content                                :  0.5- 80%. 
Melting point                                     :   52-57 c 
.Specific Gravity                                :   at 25°C : 0.8093 - 0.8157. 
Applications  
Most of the common uses of poloxamer 407 are related to its surfactant 
properties. For example, it is widely used in cosmetics for dissolving oily ingredients in 
water. It can also be found in multi-purpose contact lens cleaning solutions, where its 
purpose there is to help remove lipid films from the lens. It can also be found in some 
mouthwashes. There is a research ongoing for using poloxamer 407 for aligning severed 
blood vessels before gluing them surgically.  
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Solubility  
 Poloxamer 407 is a hydrophilic non-ionic surfactant of the more general class of 
copolymers known as poloxamers. Poloxamer 407 is a triblock copolymer consisting of a 
central hydrophobic block of polypropylene glycol flanked by two hydrophilic blocks of 
polyethylene glycol 
Stability and storage conditions  
Poloxamers are stable matrials. Aqueous solution are stable in a present of acids 
,alkalis, metal ions. However, aqueous solutions do support mold growth. The Bulk 
material  should be stored in a well closed container in a cool, dry place. 
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6.3 EXCIPIENTS PROFILE 
6.31  DICHLOROMETHANE   
Synonyms                                      :   Methane dichloride;  
                                                          Methylene bichloride; 
                                                          Methylene chloride; Methylene dichloride 
Molecular Formula                      :    CH2Cl2 
Molecular Weight                        :    84.93 
Chemical Name                            :    Dichloromethane 
Structural Formula                        :              
Description                                   :   Dichloromethane is colorless, volatile liquid with   
                                                         a moderately sweet aroma is widely used as a                                                          
                                                         solvent. Although it is not miscible with water,   
                                                         it  is miscible with many organic solvents. 
Functional category                       :   Solvent, detergent, vesicant foaming agent. 
Density                                          :   1.33 g/cm3, liquid. 
Viscosity                                        :   0.449 mPa's at 150C, 0.393 mPa's at 300C.  
Boiling Point                                 :   39.8-40.0ºC    
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Solubility                                       :   Slightly soluble (1.38 g/100 mL) in water 
                                                          at 20°C; soluble in carbontetrachloride; miscible  
                                                          in ethanol, Diethyl ether and dimethylformamide 
Stability and  
storage condition                         :   Stable upto 600c, it's vapour is nonflammable and  
                                                       is not explosive when mixed with air. But may       
                                                       form explosive mixtures in atmospheres with   
                                                       higher oxygen content.  
Applications in pharmaceutical formulation: 
Manufacturing of Polycarbonate, Phenolic, Rayon yarn, Solvent for Cellulose 
Acetates, Photo – resist, Tablet film coatings, Aerosol Propellant, Refrigerant, Adhesives 
for Polyethylene Methacrylate. 
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6.3.2. TWEEN 80 
Synonyms                                      :   Polyoxyethylene (20) sorbitan monooleate  
                                                          (x)-sorbitan mono-9-octadecenoate poly(oxy- 
                                                          1,2-ethanediyl) Alkest TW 80;  
                                                          POE (20) sorbitan monooleate  
Molecular Formula                       :   C64H124O26 
Molecular Weight                         :   428.600006103516 
Chemical Name                             :   Tween 80 
Structural Formula                       : 
                
Functional category                      :   Emulsifier, foaming agent, lubricant, 
                                                         solubilizer, surfactant 
Description                                    :   Amber-colored viscous liquid. pH (5% aqueous   
                                                         solution) 5-7.Faint odor and bitter taste 
Density                                           :   1.06-1.09 g/ml, oily liquid     
Viscosity                                         :   375-480 m.Pa.s at 250C. 
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Boiling point                                  :   >100.  
Solubility                                        :   Easily soluble in cold water, hot water. Soluble  
                                                             in methanol.Soluble in Toluene, alcohol,            
                                                             cottonseed oil, corn oil, Ethyl Acetate. 
                                                             Insoluble in mineral oil. 
Stability and  
storage condition                           :   Keep container tightly closed, cool and well- 
                                                         Ventilated area.Do not store above 32.2°C                       
                                                          (90°F). Preferably store at temperature between                
                                                          50 deg F to 90 deg F. 
Applications in pharmaceutical formulation 
Polysorbate 80 is an excipient that is used to stabilize aqueous formulations of 
medications for parenteral administration, and used as an emulsifier in the manufacture of 
the popular anti-arrhythmic amiodarone. It is also used as an excipient in some European 
and Canadian influenza vaccines. It is also used in the culture of Mycobacterium 
tuberculosis in Middle brook 7H9 broth. 
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7. MATERIALS & INSTRUMENTS 
Table-2 
7.1. MATERIALS USED 
S.NO 
 
INGREDIANTS AND 
REAGENTS 
MANUFACTURER AND 
SUPPLIER 
1 Gliclazide Mahalakshmi chemicals pvt.ltd 
hyderabad. 
2 Poloximer 407 Signant chemical corp.  pvt.ltd, 
Mumbai. 
3  Tween 80 Loba chemie pvt.ltd, Mumbai. 
4 Dichloromethane Medrich Pvt. Ltd 
5 Ethanol Medrich Pvt. Ltd 
   
 
Table-3 
7.2 INSTRUMENTS USED 
S.NO 
 
INSTRUMENTS COMPANY 
1 Digital balance Shimadzu ELB 300,Chennai 
2 Probe sonificator Elektro craft India Pvt.Ltd, 
Mumbai. 
3 Orbitek shaker Orbitek shaker, chenni. 
4 Dissolution apparatus USP XXIII Veego tablet dissolution 
apparatus, Mumbai 
5 Double beam UV 
spectrophotometer 
Perkin Elmer Lambda-25 
UV/VIS spectrometer. 
6 FTIR Perkin Elmer Lambda-25 
UV/VIS spectrometer 
7 SEM Shimadzu ELB,Chennai 
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8. METHODOLOGY 
8.1 PREFORMULATION STUDIES 
The formulation of any drug substance in to dosage form, it is essential that drug 
and polymer should be chemically and physically characterized. Preformulation studies 
give the information need to define the nature of drug substance and provide a frame 
work for a drug combination with pharmaceutical exciepients in the fabrication of a 
dosage form. 
COMPATIBILITY STUDIES 
              One of the requirement for the selection of suitable exciepients or carrier for 
pharmaceutical formulation is its compatibility. Therefore in the present work a study 
was carried out by using FTIR spectrophotometer and Differential scanning calorimeter 
(DSC) to find out if there is any possible chemical interaction of Gliclazide with 
poloxamer, ethyl cellulose (EC). 
a) Fourier Transform Infrared Spectrophotometer (FTIR) (46) 
Compatibility study of drug with the excipients was determined by FTIR 
Spectroscopy using SHIMADZU- FTIR 410 model. The pellets were prepared at high 
compaction pressure by using KBr and the ratio of sample to KBr is 1:100.The pellets 
thus prepare were examined and the spectra of drug and other ingredients in the 
formulation were compared with that of the original spectra.  
b) Differential scanning calorimeter (DSC) (47) 
Differential scanning calorimeter is used to measure the specific heat and 
enthalpies of transition. When a sample undergoes a thermal transition, the power to the 
heater is adjusted to maintain the temperature, and a signed proportional to the power 
difference is plotted on the second axis of the recorder is known as thermogram. The area 
under the resulting curve is direct measure of the heat of transition. Thermograms were 
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obtained by using a differential scanning colorimeter at a heating rate 150C/min over a 
temperature range of 0 to 10000C.The sample was hermetically sealed in an aluminium 
crucible. Nitrogen gas was purged at the rate of 100 ml/min. For maintain the inert 
atmospheres. 
8.2 CONSTRUCTION OF STANDARD CURVE FOR GLICLAZIDE: 
Gliclazide can be estimated spectrophotometrically at 224 nm as it obeys Beer's-
Lambert's law limit is the range of 5-25 µg/ml. 
Preparation of reagents  
Preparation of 7.4 buffer(48) 
 Dissolve 8.5 ml of concentrated HCl in 1000 ml of distilled water. 
Preparation of standard drug solution 
Stock solution: 
  100 mg of Gliclazide was dissolved in 100 ml of 7.4 pH, to get a solution of 
1000 µg/ml concentration. 
Standard solution 
 10 ml of stock solution was made to 100 ml with 7.4 pH thus giving a 
concentration of 100 µg/ml. Aliquot of standard drug solution ranging from 0.5 ml, 1 ml, 
1.5 ml, 2 ml and 2.5 ml were transferred into 10 ml volumetric flask and were diluted up 
to the mark with 7.4 pH. Thus the final concentration ranges from 2-10 µg/ml. 
Absorbance of each solution was measured at 235 nm against 7.4 pH as a blank. A plot of 
concentrations of drug versus absorbance was plotted. 
The linear regression analysis was done on absorbance data points. A straight line 
equation was generated to facilitate the calculation of amount of drug. 
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8.3 Calculation of controlled release dose  
 Required dose = conventional dose (1+0.693 × τ/t 1/2) 
 Where as,  τ    = Duration of dose 
                           t    = Half life of drug 
 Required dose = 4 (1+0.693 × 12/5)  
 Required dose = 10mg of Gliclazide. 
8.4 PREPARATION OF MICROSPHERES BY EMULSION SOLVENT 
DIFFUSION EVAPORATION TECHNIQUE (27) 
The formulations of different batches of Gliclazide microspheres are given in 
table 4.  
Accurately weighed amount of Gliclazide and poloxamer were dissolved in a 
mixture of Dichloromethane (DCM): Ethanol (ETN) (1:1) at room temperature. This 
solution was poured into 100ml distilled water containing 0.1% Tween 80 maintained at a 
temperature of 300-400C.The resultant emulsion was stirred with a propeller type agitator 
at 1200 rpm for 45 mins to allow volatile solvent to evaporate. The resultant 
microspheres were filtered and dried. 
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Table-4 
Formulation 
code 
Drug:Polymer Gliclazide  
(mg ) 
Poloxamer in (mg)  
F1 1:1 10 10  
F2 1:2 10 20  
F3 1:3 10 30  
F4 1:4 10 40  
F5 1:5 10 50  
F6 1:6 10 60  
 
8.5 EVALUATION OF THE PREPARED MICROSPHERES 
8.5.1 Particle size analysis (49) 
The particle size of the microsphere is determined by using the optical 
microscopy method. Microspheres are counted for particle size using a calibrated optical 
microscope. 
8.5.2 Shape and surface characterization (50) 
The shape and surface characterization of microspheres are observed under 
scanning electron microscope(SEM).The microspheres are mounted directly on the SEM 
sample stub, using double-sided sticking tape, and coated with gold film(thickness 
200mm) under reduced pressure (0.001 tort) and photographed. 
8.5.3 Determination of drug content (51) 
Accurately weighed 10 mg of crushed microspheres were dissolved in PH 7.4 
buffer solution and then transferred to 100 ml volumetric flask. The volume was made up 
to 100mL with 0.1N HCl. The solution was filtered using Whatman filter paper no. 41. 
The samples were assayed for drug content using UV spectrophotometer at 235 nm. 
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8.5.4 Determination of percentage yield of microspheres (52) 
Thoroughly dried microspheres were collected and weighed accurately. The 
percentage yield was then calculated using formula given below. 
percentage yield =
Mass of microspheres obtained 
Total weight of drug and polymer  
 X100 
8.5.5 Encapsulation efficiency (53) 
Encapsulation efficiency of microspheres was calculated using the following formula; 
Encapsulation eficiency =
Estimated drug content%
theoretical drug content% 
 X100 
8.5.6 In-vitro release studies of drug release (54) 
Dissolution parameters 
Medium                                         :   In pH 7.4 buffer solution 
Apparatus                                     :   USP-Type I (basket). 
RPM                                             :   100 
Temperature                                 :   370 ± 0.50c 
Medium volume                            :   900ml 
Sampling Time Interval                 :   1, 2, 3…….12 hours. 
Detected by                                    :   Double beam UV-visible spectrophotometer(nm).  
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Procedure 
In-vitro drug release studies were carried out using the rotating basket method 
specified in USP XXIII dissolution apparatus (Apparatus I) with 100 rpm speed at 37 ± 
0.50C. Dissolution was carried out in pH 7.4 buffer solution. The weighed amount of 
microspheres were wrapped in muslin cloth and kept in baskets. The drug release studies 
were carried out in 900 ml of pH 7.4 buffer solution as dissolution media. Samples were 
withdrawn at predetermined time interval (1 h) from each dissolution vessel, filtered 
using Whatman filter paper; samples were analyzed for drug at 235 nm using a UV 
visible double beam spectrophotometer. 
8.4.8 Kinetics of drug release (55) 
In order to understand the mechanism and kinetic of drug release, the drug release 
data of the in-vitro dissolution study are analysed with various kinetic model like zero 
order, first order, higuchi’s, peppa's and coefficient of correlation (r) values are calculated 
for the linear curves by regression analysis of the above plots. 
Table-5 
Mechanism of drug release as per korsemeyer equation/peppa's model 
S.No N Value Drug release 
1. n < 0.5 Fickian release 
2. 0.5<n<1 Non- Fickian release 
3. n>1 Case II transport 
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9. RESULTS 
9.1 COMPATABILITY STUDIES 
9.1.1 Fourier Transform Infrared Spectrophotometer (FTIR) 
Infrared spectra for pure drug Gliclazide, poloxamer407 vand physical mixture of 
drug and polymer were determined to check the interaction of drug in the polymer mixture, 
their spectrums are shown in figures 1 to3. 
Figure:1  FTIR SPECTRA OF GLICLAZIDE 
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Figure:2  FTIR SPECTRA OF POLOXAMER 407 
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Figure:3  FTIR SPECTRA OF GLICLAZIDE + POLOXAMER 407 
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9.1.2 Differential scanning calorimeter (DSC)  
DSC provides information about physical properties of sample as crystalline or 
amorphous nature and demonstrates the possible interaction between drug and other 
polymers. 
DSC thermogram of Gliclazide, poloxamer407 and physical mixture of drug and 
polymers are shown in figures 4-6. Gliclazide showed characteristic endothermic peak at 
173.770C,  poloxamer407 showed at 59.760C.  
Figure:4 
                         DSC SPCTRA OF PURE DRUG (GLICLAZIDE) 
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Figure:5 
DSC SPCTRA OF POLYMER (POLOXAMER) 
 
 
Figure:6 
DSC SPCTRA GLICLAZIDE +POLOXAMER 
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9.2 CONSTRUCTION OF STANDARD CURVE FOR GLICLAZIDE 
                                                            Table:6 
Standard curve for Gliclazide 
S.NO Concentration in µg/ml 
 
Absorbance at 235 nm 
1 2 0.210 
2 4 0.401 
3 6 0.606 
4 8 0.810 
5 10 0.988 
Slope 0.100 
Correlation coefficient 0.999 
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Figure:7 
STANDARD CURVE FOR GLICLAZIDE IN pH 7.4 
 
9.3  DATA FOR PARTICLE SIZE OF GLICLAZIDE MICROSPHERES (Table:7) 
                                                          
 
  
 
 
 
 
 
 
                         *Each value represents the mean±S.D. of three experiments 
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CONCENTRATION (µg/ml)
STANDURARD CURVE OF GLICLAZIDE IN PH7.4
Series1
Linear (Series1)
 
FORMULATION CODE 
 
MEAN PARTICLE SIZE (µm) 
F1 127±1.563 
F1 157±2.039 
F3 168±0.935 
F4 217±1.178 
F5 247±1.825 
F6 265±1.509 
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9.4 SHAPE AND SURFACE CHARACTERIZATION OF THE PREPARED 
GLICLAZIDE MICROSPHERES (SEM) 
Scanning electron micrograph (SEM) of the prepared  microspheres of Gliclazide  is 
showed in figures 8-10 at different magnifications. SEM images revealed that the 
microspheres were spherical in shape with a smooth surface morphology. 
Scanning electron micrograph (SEM) of the prepared  microspheres of Gliclazide  
formulation 
Figure:8 
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Figure:9 
 
 
 
Figure:10  
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9.5. DATA FOR PERCENTAGE DRUG CONTENT OF GLICLAZIDE      
       MICROSPHERES 
Table-8 
FORMULATION CODE PERCENTAGE DRUG 
CONTENT 
 
F1 70.56±2.274 
F2 75.71±0.991 
F3 79.21±2.428 
F4 84.83±1.541 
F5 94.57±1.162 
F6 98.16±1.357 
                 *Each value represents the mean±S.D. of three experiments 
 9.6 DATA FOR PERCENTAGE YIELD OF GLICLAZIDE MICROSPHERES 
Table-9 
FORMULATION CODE PERCENTAGE YIELD 
OF MICROSPHERES 
F1 61±1.862 
F2 66±1.325 
F3 69±1.472 
F4 74±2.153 
F5 79±1.025 
F6 81±1.951 
                     *Each value represents the mean±S.D. of three experiments 
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9.7. DATA FOR PERCENTAGE DRUG ENTRAPMENT EFFICIENCY OF  
      GLICLAZIDE MICROSPHERES 
Table:10 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
code 
 
 
Theoretical 
drug content in 
% 
Practical drug 
content in % 
Entrapment 
efficiency in % 
F1 
 
6.02 5.38 64.45±2.186 
F2 
 
8.15 6.73 72.44±2.38 
F3 
 
8.15 6.54 77.14±1.171 
F4 
 
9.45 7.29 80.24±1.436 
F5 
 
12.92 9.36 82.57±1.325 
F6 
 
15.25 9.83 89.36±2.428 
 
60 
 
9.8 DATA FOR INVITRO DRUG RELEASE OF GLICLAZIDE MICROSPHERES:- 
                                                         Table: 11 
In Vitro Drug release of Formulation F1 
Time 
(hrs) 
 
Absorbance 
(nm) 
Concentration 
µg/ml 
Amount of 
drug release 
Cum % of 
drug release 
0 
 
0 0 0 0 
1 
 
0.009 0.232 2.094 10.47±2.145 
2 
 
0.012 0.308 2.78 13.92±0.978 
3 
 
0.017 0.435 3.92 19.63±1.689 
4 
 
0.021 0.537 4.84 24.20±2.146 
5 
 
0.024 0.624 5.62 28.14±1.507 
6 
 
0.031 0.795 7.16 35.81±1.307 
7 
 
0.037 0.936 8.43 42.16±1.624 
8 
 
0.042 1.073 9.66 48.33±1.364 
9 
 
0.048 1.209 10.88 54.42±1.759 
10 
 
0.052 1.323 11.91 59.56±1.158 
11 
 
0.056 1.408 12.67 63.39±2.076 
12 
 
0.058 1.472 13.25 66.25±1.379 
                     *Each value represents the mean±S.D. of three experiments 
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Figure:11 
IN-VITRO DRUG RELEASE PLOT FOR F1 
 
 
Figure:12 
KINETIC PLOT OF ZERO ORDER DRUG RELEASE FOR F1 
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Figure:13 
KINETIC PLOT OF FIRST ORDER DRUG RELEASE FOR F1 
 
 
Figure: 14 
KINETIC PLOT OF HIGUCHI DRUG RELEASE FOR F1 
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Figure: 15 
KINETIC PLOT OF KORESMEYER – PEPPA’S DRUG RELEASE FOR F1 
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Table:12 
 In -Vitro Drug release of Formulation F2 
Time 
(hrs) 
 
Absorbance 
(nm) 
Concentration 
µg/ml 
Amount of 
drug release 
Cum % of 
drug release 
0 
 
0 0 0 0 
1 
 
0.014 0.36 3.24 16.21±1.406 
2 
 
0.018 0.47 4.28 21.42±1.819 
3 
 
0.022 0.56 5.06 25.32±1.462 
4 
 
0.028 0.70 6.36 31.82±1.879 
5 
 
0.032 0.82 7.44 37.21±1.094 
6 
 
0.038 0.97 8.76 43.81±1.249 
7 
 
0.042 1.07 9.65 48.27±1.657 
8 
 
0.048 1.2 10.86 54.31±1.953 
9 
 
0.054 1.37 12.37 61.88±2.543 
10 
 
0.059 1.49 13.44 67.21±1.527 
11 
 
0.063 1.59 14.31 71.58±1.249 
12 
 
0.065 1.64 14.76 73.82±1.315 
 
                      *Each value represents the mean±S.D. of three experiments 
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Figure: 16 
IN-VITRO DRUG RELEASE PLOT FOR F2  
 
 
Figure:17 
KINETIC PLOT OF ZERO ORDER DRUG RELEASE FOR F2 
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Figure: 18 
KINETIC PLOT OF FIRST ORDER DRUG RELEASE FOR F2 
  
 
Figure: 19 
KINETIC PLOT OF HIGUCHI DRUG RELEASE FOR F2 
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Figure: 20  
KINETIC PLOT OF KORESMEYER - PEPPA'S DRUG RELEASE FOR F2 
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Table :13 
In- Vitro Drug release of Formulation F3 
Time 
(hrs) 
 
Absorbance 
(nm) 
Concentration 
µg/ml 
Amount of 
drug release 
Cum % of 
drug release 
0 0 0 0 0 
1 0.011 0.294 2.65 13.25±0.185 
2 0.014 0.370 3.33 16.67±1.209 
3 0.018 0.474 4.27 21.36±1.115 
4 0.021 0.548 4.93 24.68±1.462 
5 0.025 0.626 5.63 28.18±1.325 
6 0.030 0.764 6.88 34.41±1.415 
7 0.036 0.919 8.27 41.37±1.981 
8 0.042 1.056 9.50 47.54±1.359 
9 0.048 1.218 10.96 54.83±1.628 
10 0.055 1.394 12.54 62.74±1.537 
11 0.061 1.536 13.82 69.14±1.645 
12 0.068 1.708 15.37 76.87±1.963 
                       *Each value represents the mean±S.D. of three experiments 
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Figure: 21 
IN-VITRO DRUG RELEASE PLOT FOR F3 
 
 
Figure: 22 
KINETIC PLOT OF ZERO ORDER DRUG RELEASE FOR F3 
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Figure: 23 
KINETIC PLOT OF FIRST ORDER DRUG RELEASE FOR F3 
 
 
Figure: 24 
KINETIC PLOT OF HIGUCHI DRUG RELEASE FOR F3 
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Figure: 25 
        KINETIC PLOT OF KORESMEYER - PEPPA'S DRUG RELEASE FOR F3  
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Table: 14 
    In- Vitro Drug release of Formulation F4 
Time 
(hrs) 
Absorbance 
(nm) 
Concentration 
µg/ml 
Amount of 
drug release 
Cum % of 
drug release 
0 0 0 0 0 
1 0.0126 0.315 2.84 14.21±1.691 
2 0.0173 0.433 3.9 19.50±1.052 
3 0.021 0.547 4.92 24.63 ± 1.527 
4 0.029 0.728 6.56 32.8±1.694 
5 0.034 0.86 7.74 38.73±1.653 
6 0.038 0.96 8.64 43.21±1.951 
7 0.044 1.11 9.99 49.98±1.668 
8 0.048 1.21 10.94 54.72±1.364 
9 0.054 1.36 12.24 61.24±1.495 
10 0.059 1.481 13.33 66.65±1.724 
11 0.064 1.608 14.47 72.37±1.082 
12 0.071 1.776 15.99 79.96±1.619 
                     *Each value represents the mean±S.D. of three experiments 
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Figure:26 
IN-VITRO DRUG RELEASE PLOT FOR F4  
 
 
Figure:27 
KINETIC PLOT OF ZERO ORDER DRUG RELEASE FOR F4 
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Figure:28 
KINETIC PLOT OF FIRST ORDER DRUG RELEASE FOR F4 
 
 
Figure:29 
KINETIC PLOT OF HIGUCHI DRUG RELEASE FOR F4 
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Figure:30 
      KINETIC PLOT OF KORESMEYER - PEPPA'S DRUG RELEASE FOR F4 
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Table-15 
In Vitro Drug release of Formulation F5 
Time 
(hrs) 
 
Absorbance 
(nm) 
Concentration 
µg/ml 
Amount of 
drug release 
Cum % of 
drug release 
0 0 
 
0 0 0 
1 0.014 
 
0.352 3.17 15.87±1.524 
2 0.016 
 
0.406 3.65 18.27±1.432 
3 0.024 
 
0.62 5.58 27.90±1.586 
4 0.028 
 
0.724 6.52 38.85±2.054 
5 0.034 
 
0.863 7.77 43.17±2.364 
6 0.038 
 
0.959 8.63  
7 0.045 
 
1.142 10.27 51.39±1.561 
8 0.053 
 
1.342 12.08 60.42±1.429 
9 0.060 
 
1.516 13.65 68.25±1.357 
10 0.066 
 
1.661 14.95 74.76±1.438 
11 0.071 
 
1.790 16.11 80.56±1.215 
12 0.075 
 
1.882 16.94 84.73±1.365 
                        *Each value represents the mean±S.D. of three experiments 
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Figure: 31 
IN-VITRO DRUG RELEASE PLOT FOR F5 
 
 
Figure: 32 
KINETIC PLOT OF ZERO ORDER DRUG RELEASE FOR F5 
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Figure: 33 
KINETIC PLOT OF FIRST ORDER DRUG RELEASE FOR F5 
 
 
Figure: 34 
KINETIC PLOT OF HIGUCHI DRUG RELEASE FOR F5 
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Figure : 35 
KINETIC PLOT OF KORESMEYER - PEPPA'S DRUG RELEASE FOR F5 
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Table-16 
In- Vitro Drug release of Formulation F6 
Time 
(hrs) 
 
Absorbance 
(nm) 
Concentration 
µg/ml 
Amount of 
drug release 
Cum % of 
drug release 
0 
 
0 0 0 0 
1 
 
0.0154 0.387 3.484 17.42±0.975 
2 
 
0.023 0.576 5.186 25.93±2.401 
3 
 
0.0316 0.790 7.118 35.59±1.246 
4 
 
0.042 1.05 9.492 47.46±1.652 
5 
 
0.05 1.257 11.316 56.58±1.752 
6 
 
0.053 1.33 12.044 60.22±1.462 
7 
 
0.060 1.503 13.528 67.64±1.325 
8 
 
0.066 1.67 15.054 75.27±1.425 
9 
 
0.073 1.826 16.438 82.19±1.546 
10 
 
0.077 1.940 17.466 87.33±1.159 
11 
 
0.081 2.031 18.286 91.43±1.879 
12 
 
0.083 2.085 18.77 93.85±1.042 
                      *Each value represents the mean±S.D. of three experiments 
 
 
 
 
81 
 
 
Figure: 36 
IN-VITRO DRUG RELEASE PLOT FOR F6  
 
 
Figure: 37 
KINETIC PLOT OF ZERO ORDER DRUG RELEASE FOR F6 
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Figure: 38 
KINETIC PLOT OF FIRST ORDER DRUG RELEASE FOR F6 
 
 
Figure: 39 
KINETIC PLOT OF HIGUCHI DRUG RELEASE FOR F6 
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Figure: 40 
KINETIC PLOT OF KORESMEYER - PEPPA'S DRUG RELEASE FOR F6  
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DATA  FOR  IN-VITRO  CUMULATIVE  PERCENTAGE  DRUG  RELEASE  OF  F1  
TO  F6  FORMULATIONS 
TABLE:17 
 
 
 
 
TIME in  
Hrs 
 
FORMULATION CODE AND CUMULATIVE  PERCENTAGE  OF DRUG  
RELEASE 
 F1 F2 F3 
 
F4 F5 F6 
1 10.47 16.21 13.25 14.21 15.87 17.42 
2 13.92 21.42 16.67 19.50 18.27 25.93 
3 19.63 25.32 21.36 24.63 27.90 35.59 
4 24.20 31.82 24.68 32.8 32.62 47.46 
5 28.14 37.21 28.18 38.73 38.85 56.58 
6 35.81 43.81 34.41 43.21 43.17 60.22 
7 42.16 48.27 41.37 49.98 51.39 67.64 
8 48.33 54.31 47.54 54.72 60.42 75.27 
9 54.42 61.88 54.83 61.24 68.25 82.19 
10 59.56 67.21 62.74 66.65 74.76 87.33 
11 63.39 71.58 69.14 72.37 80.56 91.43 
12 66.25 73.82 76.87 79.96 84.73 93.85 
 FOR  COMPARATIVE IN
RELEASE  OF  F1  TO  F6  FORMULATIONS
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Figure: 41 
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IN-VITRO KINETIC DATA OF F1 TO F6 FORMULATIONS 
Table-18 
 
 
 
Zero-order 
Plots 
First- order 
Plots 
Higuchi's 
Plots 
Koresmeyer- 
Peppa’s plot 
 
Possible 
Drug 
Release 
mechanism 
Formula 
Code 
Regression 
Coefficients 
(R2) 
Regression 
Coefficients 
(R2) 
Regression 
Coefficients 
(R2) 
Slope 
(n) 
Regression 
Coefficients 
(R2) 
 
F1 0.993 
 
0.983 0.933 0.806 0.909 Zero-order Non-
Fickian release 
F2 0.985 
 
0.981 0.961 0.82 0.923 Zero-order Non-
Fickian release 
F3 0.985 
 
0.923 0.899 0.84 0.934 Zero-order Non-
Fickian release 
F4 0.992 
 
0.961 0.955 0.85 0.957 Zero-order Non-
Fickian release 
F5 0.992 0.946 0.938 0.736 0.967 Zero-order Non-
Fickian release 
F6 0.968 0.961 0.979 0.708 0.934 Zero-order Non-
Fickian release 
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  10. DISCUSSION 
Gliclazide is an anti-diabetic drug comes under the category of second-generation 
sulfonylurea and is very potent drug. It acts as insulin sensitizer that has been widely used in 
management of NIDDM. Its half life is 5 hrs and more than 99% bind to plasma proteins. It is 
absorbed from entire GIT and is mainly excreted through urine remaining through feces. 
Gliclazide should be administered with breakfast or the first main meal.  and recommended 
dose is minimum 20mg to maximum 80mg per day. 
In the present work efforts have been made to develop microspheres for controlled 
drug delivery of gliclazide by emulsion solvent diffusion-evaporation technique using various 
proportions of poloximer 407 as a polymer. 
Polymer concentration is the major factor for controlling the drug release. Poloxamer 
407 formulations led to enhanced solubilisation of poorly water-soluble drugs and prolonged 
release profile for many galenic applications (e.g., oral, rectal, topical, ophthalmic, nasal and 
inject able preparations). Poloxamer 407 formulations having the dissolution follow a zero-
order kinetics due to the rapid dissolution of Poloxamer 407 in the receptor fluid and present 
advantages of promoting stabilization and water dissolution of many pharmacological drugs. 
New trends suggest combining Poloxamer 407 with other copolymers (e.g., thickening 
agents, other types of poloxamers). 63 
The FTIR and DSC spectral analysis showed that there was no appearance or 
disappearance of any characteristic peak of pure drug, physical mixture of drug and polymer, 
which confirms the absence of chemical interaction between the drug and polymer. 
Microspheres were prepared using a gradually increasing polymer concentration in 
combination with a fixed dose concentration of the drug to assess the effect of polymer 
concentration on the size of the microspheres. The mean particle size or average diameter of 
the microspheres significantly increased with increasing polymer concentration. Larger 
particles developed due to increased viscosity of the medium with an increasing higher 
polymeric concentration. This is because at higher viscosities there is enhanced interfacial 
tension and diminished shearing efficiency. Thus, the higher polymeric concentrated 
microspheres influence the particle size  and drug release of the microspheres. 
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The surface morphology was observed by scanning electron microscopic photographs, 
which showed that the fabricated microspheres were spherical with a smooth in surface 
(figures 11, 12, 13).  
The percentage yield and drug entrapment efficiency were determined for all the 
formulations. As the concentration of polymer increases both percentage yield and 
entrapment efficiency are also increased. The drug content was depends up on the 
concentration of polymers, as the concentration of polymer increases the drug content also 
increases due to the rapid dissolution of Poloxamer 407 in the receptor fluid. 
The prepared microspheres then subjected to dissolution test for evaluating the in-
vitro drug release studies. The result of dissolution studies indicates that cumulative 
percentage release of microspheres significantly increased with increasing polymer 
concentration. The increased density of the polymer matrix at higher concentration results in 
an increased diffusion path length. This may decrease the overall drug release from the 
polymer matrix. Furthermore, smaller microspheres formed at a lower polymer concentration 
and having a larger surface area when exposed to the dissolution medium showed a faster 
drug release and the polymer concentration maintain the controlled drug release of the drug.  
The data obtained for in-vitro release kinetics were fitted into equations for the zero-
order, first-order, Higuchi and peppa’s release models. The interpretation of the data was 
based on the value of the resulting regression coefficients. The in-vitro drug release showed 
the highest regression coefficient values for the zero order release kinetics, indicating that the 
polymer shows the controlled release of the drug, and the slope (n) value of peppa’s 
mechanism of drug release was found to be non-fickian diffusion mechanism. 
The release profile of formulations F5 and F6, were best fitting with USFDA 
guidelines for extended drug release for 12hrs, and release of the drug not more than 20% in 
1st hr and not less than 80% in 12th hr.  
Based on the parameters like drug content 98.16%, entrapment efficiency-89.36%, 
and the cumulative percentage drug release rate 93.85% at 12th hrs, and follows zero order 
drug release kinetics and non-fickian diffusion mechanism. Hence the formulation F6 was 
considered as the best one among all the formulations. 
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11. CONCLUSION 
The study concluded that Gliclazide microspheres can be developed with poloximer 
407 polymer by Emulsion solvent diffusion-evaporation method and the results revealed that 
the formulation F6 shows desired release characteristics in the polymer ratio of (1:6)  to 
achieve the controlled drug release of drug up to 12 hours. Further in-vivo studies to be 
carried out to confirm the formulation.  
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